KKR Genetic Disorder GP LLC

SEC source: 0001140361-25-019003 · form4.xml · nonDerivative · entry 1

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

KKR Group Partnership L.P. · CIK 0001472698 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR Group Co. Inc. · CIK 0001932162 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Management LLP · CIK 0001472694 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 13,260,971

F1 · price: Reflects the sale of 6,000,000 shares of common stock of BridgeBio Pharma, Inc. (the "Issuer"), par value $0.001 per share (the "Common Stock"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $34.20 pursuant to Rule 144 of the Securities Act of 1933, as amended.

F2 · ownership.nature: The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0001140361-25-007699 · form4.xml · nonDerivative · entry 1

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

KKR Group Partnership L.P. · CIK 0001472698 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR Group Co. Inc. · CIK 0001932162 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Management LLP · CIK 0001472694 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 19,260,971

F1 · price: Reflects the sale of 6,000,000 shares of common stock of BridgeBio Pharma, Inc. (the "Issuer"), par value $0.001 per share (the "Common Stock"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $32.96 pursuant to Rule 144 of the Securities Act of 1933, as amended.

F2 · ownership.nature: The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0001140361-24-041329 · form4.xml · nonDerivative · entry 1

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

KKR Group Partnership L.P. · CIK 0001472698 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR Group Co. Inc. · CIK 0001932162 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Management LLP · CIK 0001472694 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 25,260,971

F1 · price: Reflects the sale of 5,800,000 shares of common stock of BridgeBio Pharma, Inc. (the "Issuer"), par value $0.001 per share (the "Common Stock"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $25.75 pursuant to Rule 144 of the Securities Act of 1933, as amended.

F2 · ownership.nature: The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0001140361-21-005267 · form4.xml · nonDerivative · entry 1

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

KKR Group Partnership L.P. · CIK 0001472698 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Management LLP · CIK 0001472694 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 31,060,971

F1 · price: This amount represents the $62.50 secondary public offering price per share of common stock of BridgeBio Pharma, Inc. ("Common Stock") less the underwriting discount of $2.03125 per share for shares sold pursuant to an underwritten public offering

F1 · ownership.nature: This amount represents the $62.50 secondary public offering price per share of common stock of BridgeBio Pharma, Inc. ("Common Stock") less the underwriting discount of $2.03125 per share for shares sold pursuant to an underwritten public offering

F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0001140361-20-012852 · form4.xml · nonDerivative · entry 1

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

KKR Group Partnership L.P. · CIK 0001472698 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Management LLP · CIK 0001472694 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 34,510,971

F1 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

F2 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0000899243-19-019173 · doc4.xml · derivative · entry 5

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

KKR Management LLC · CIK 0001472694 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR Management Holdings Corp · CIK 0001472692 · 10% owner

KKR Management Holdings L.P. · CIK 0001472693 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 10,178,954 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0000899243-19-019173 · doc4.xml · derivative · entry 4

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

KKR Management LLC · CIK 0001472694 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR Management Holdings Corp · CIK 0001472692 · 10% owner

KKR Management Holdings L.P. · CIK 0001472693 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 8,215,295 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0000899243-19-019173 · doc4.xml · derivative · entry 3

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

KKR Management LLC · CIK 0001472694 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR Management Holdings Corp · CIK 0001472692 · 10% owner

KKR Management Holdings L.P. · CIK 0001472693 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 15,859,312 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0000899243-19-019173 · doc4.xml · nonDerivative · entry 2

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

KKR Management LLC · CIK 0001472694 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR Management Holdings Corp · CIK 0001472692 · 10% owner

KKR Management Holdings L.P. · CIK 0001472693 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 36,900,661

F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

SEC source: 0000899243-19-019173 · doc4.xml · nonDerivative · entry 1

KKR Genetic Disorder L.P. · CIK 0001780408 · 10% owner

ROBERTS GEORGE R · CIK 0001081715 · 10% owner

KRAVIS HENRY R · CIK 0001081714 · 10% owner

KKR Management LLC · CIK 0001472694 · 10% owner

KKR & Co. Inc. · CIK 0001404912 · 10% owner

KKR Group Holdings Corp. · CIK 0001743754 · 10% owner

KKR Management Holdings Corp · CIK 0001472692 · 10% owner

KKR Management Holdings L.P. · CIK 0001472693 · 10% owner

KKR Genetic Disorder GP LLC · CIK 0001780428 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 34,253,561

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date.

F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.